TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

NCT05842785 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma

Interventions

DRUG: Phase I dose escalation
DRUG: Phase II-HNSCC
DRUG: Phase II-Advanced melanoma
DRUG: Phase II-solid tumors or lymphomas

Sponsor

Tyligand Bioscience (Shanghai) Limited